StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.85+0.41 (+1.49%)

Close on Nov 17, 2026Market cap $4.83BP/E –Yield –

Cogent Biosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Cogent Biosciences's total debt was $44.25M at Sep 30, 2025. For fiscal 2024 it was $0.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025$44.25M–
Q2 FY2025Jun 30, 2025$43.95M–
Q4 FY2024Dec 31, 2024$0–

More Cogent Biosciences figures

See a number that looks wrong?